Clinical trial · no report yet · Phase 1

ARTEMIS-001

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

NCT05276609 ↗
Unknown
Shanghai Hansoh Biomedical Co., Ltd
Standard size, estimated: 151–300 verified statements

We haven't built an HCP commentary report on ARTEMIS-001 (risvutatug rezetecan (HS-20093) in locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on ARTEMIS-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
10 posts on X
1 podcast episode

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy
Phase: Phase 1
Status: Unknown
Conditions: Advanced Solid Tumor
Interventions: HS-20093 (Phase Ia: Dose escalation); HS-20093 (Phase Ib: Dose expansion)
Arms: HS-20093 (Phase Ia: Dose escalation) · Experimental
HS-20093 (Phase Ib: Dose expansion) · Experimental
Enrollment: 177 (estimated)
Primary outcomes: Ⅰa (Dose-Escalation Stage): Maximum tolerated dose (MTD) for HS-20093
Ⅰb (Dose-Expansion Stage): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Sponsor: Shanghai Hansoh Biomedical Co., Ltd
Start: Nov 28, 2021
Primary completion: Dec 31, 2023 (estimated)
Results posted: No
Registry record: NCT05276609 · updated Feb 15, 2023

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md